Prime Medicine, Inc. (PRME)

Acerca de Prime Medicine, Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Al 3 de noviembre de 2026, la acción de Prime Medicine, Inc. (PRME) subió con fuerza a $4.57, un alza de 2.86% (+$0.13) frente al cierre anterior. En la sesión, las acciones han operado entre $4.50 y $4.88. Eso ubica a PRME cerca de la mitad de su rango de 52 semanas, de $2.67 a $5.91. Prime Medicine, Inc. opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $805.31 millones, con cerca de 1.86 millones de acciones negociadas.

Últimas noticias de PRME

• Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Yahoo Finance· 29 oct, 2:41 a.m. ET
• PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Editsstocktwits.com· 28 oct, 3:34 p.m. ET
• Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyYahoo Finance· 12 oct, 11:24 a.m. ET
• Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson DiseaseYahoo Finance· 5 oct, 8:00 a.m. ET
• Temporary Weakness in Intellia Stock Seems Like a Buying Opportunitybarchart.com· 29 sep, 9:00 a.m. ET
• Prime Medicine stock surges on FDA IND clearanceYahoo Finance· 24 sep, 4:47 p.m. ET
• Anthropic AI Discovery Gene-Editing Stocks FallingYahoo Finance· 24 sep, 8:46 a.m. ET
• CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?stocktwits.com· 23 sep, 5:49 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de PRME en un solo lugar? Crea una cuenta gratis →

• $PRME Prime Medicine, Inc. (NASDAQ: PRME) has cleared a legal obstacle and advanced two gene-editing programs. Here is what investors should watch as clinical progress meets funding pressure. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-prime-medicine…

  @BioTechHealthX· 3 nov, 12:46 p.m. ET

• $PRME entry on the close yesterday, bank participation today 💎💎💎💎

  @Alien1980· 3 nov, 9:46 a.m. ET· Alcista

• $PRME bounced off 9 D EMA, this beast is flying under the radar

  @Blankbeanie· 3 nov, 9:41 a.m. ET· Alcista

• $PRME Got some bids placed for December $5C’s. Just profit money, don’t be stupid like me.

  @PorkchopSquats· 2 nov, 1:34 p.m. ET

• $PRME The drop is across the board - NTLA, CRSP, BEAM, EDIT. What these guys have special is of course their impending money raise - whether it's a deal or a dilution is probably the biggest short term driver after the sector and global trends. Given the leverage these day…

  @quark_n_jaguar· 2 nov, 12:14 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →